APA (7th ed.) Citation

Chen, L., Sun, R., Xu, J., Zhai, W., Zhang, D., Yang, M., . . . Lu, B. (2020). Tumor-Derived IL33 Promotes Tissue-Resident CD8 + T Cells and Is Required for Checkpoint Blockade Tumor Immunotherapy. Cancer immunology research, 8(11), 1381. https://doi.org/10.1158/2326-6066.CIR-19-1024

Chicago Style (17th ed.) Citation

Chen, Lujun, et al. "Tumor-Derived IL33 Promotes Tissue-Resident CD8 + T Cells and Is Required for Checkpoint Blockade Tumor Immunotherapy." Cancer Immunology Research 8, no. 11 (2020): 1381. https://doi.org/10.1158/2326-6066.CIR-19-1024.

MLA (9th ed.) Citation

Chen, Lujun, et al. "Tumor-Derived IL33 Promotes Tissue-Resident CD8 + T Cells and Is Required for Checkpoint Blockade Tumor Immunotherapy." Cancer Immunology Research, vol. 8, no. 11, 2020, p. 1381, https://doi.org/10.1158/2326-6066.CIR-19-1024.